Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Liposomal Doxorubicin, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
NCT00944801Phase 2Completed
- Sponsor
- University of Regensburg
- Start
- Jul 2002
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in glioblastoma (GBM), sponsored by University of Regensburg. Primary endpoint: Progression-Free Survival Probability at 12 Months. Started Jul 2002; status: completed.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00944801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00944801.